JSPR (Jasper Therapeutics) Moat Score: 3/10 (As of Jul. 02, 2026)


JSPR Jasper Therapeutics Inc JSPR
24 GF Score
Price $0.43
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics Moat Score?

Jasper Therapeutics JSPR -5.19% 24 Moat Score is 3 as of Jul. 02, 2026. GuruFocus rates JSPR with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, Jasper Therapeutics ranks better than 75.5% on this metric.

Jasper Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Jasper Therapeutics has No Moat: Jasper Therapeutics Inc has very weak competitive advantages. While it may possess some valuable intellectual property, it lacks market leadership, strong brand strength, and significant regulatory barriers, making its moat transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Jasper Therapeutics might have No Moat - Very weak/transient advantages.

Jasper Therapeutics  (NAS:JSPR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Jasper Therapeutics Moat Score Related Terms

JSPR vs CVKD, BRTX, APRE: Moat Score Comparison

For the Biotechnology subindustry, Jasper Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jasper Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's Moat Score falls into.


JSPR
24GF Score
Jasper Therapeutics Inc JSPR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Jasper Therapeutics (JSPR) has a Moat Score of 3 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Jasper Therapeutics ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Jasper Therapeutics' Moat Score too high?
Jasper Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Jasper Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Jasper Therapeutics ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jasper Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' Moat Score compare to CVKD and BRTX?
According to the Biotechnology industry distribution chart, Jasper Therapeutics ranks #343 out of 1400 companies for Moat Score. This places Jasper Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Jasper Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jasper Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jasper Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Jasper Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current Moat Score is 3 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
24GF Score

Get the complete analysis for JSPR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price